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1. Introduction
Human papillomavirus (HPV) infection is an extremely common sexually transmitted
infection (STI) in the United States (U.S.) [1], with most estimates of prevalence among
asymptomatic males over 20% [2,3]. Infection can occur soon after sexual debut, and the
risk increases with the introduction of new sexual partners [4]. Although most HPV
infections in males clear within one year without intervention [5], persistent infections can
have serious health consequences. Oncogenic HPV types (mainly types 16 and 18) are
responsible for almost all anal cancers, 40% of penile cancers, and 25%–35% of oral cancers
[6,7]. Nononcogenic HPV types 6 and 11 cause genital warts [8,9], a diagnosis reported by
about 4% of men in the U.S [10]. Female partners of HPV-infected males are at increased
risk of cervical disease [11,12].
The U.S. Food and Drug Administration (FDA) approved a quadrivalent HPV vaccine
against types 6, 11, 16, and 18 for use in females aged 9–26 years in 2006 [13]. The
Advisory Committee on Immunization Practices (ACIP) currently recommends routine
vaccination of females aged 11–12 years with catch-up vaccination for females through age
26 [13]. Recently, the FDA approved the quadrivalent HPV vaccine for use in males aged 9–
26 years [14], as it was found to be efficacious in reducing the incidence of persistent HPV
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infection and external genital lesions among young men [15,16]. Because HPV is an STI,
vaccinating males against HPV may also have indirect benefit for females due to reduced
transmission. In October 2009, the ACIP made a provisional permissive recommendation
regarding use of HPV vaccine among males aged 9–26 years [17], which was published in
final form in May 2010 [18]. The permissive recommendation states that healthcare
providers may provide the vaccine to patients, but the vaccine is not included in the routine
vaccination schedule for males. The ACIP also recommended the Vaccines for Children
(VFC) program, which provides vaccines at no cost to children who may not otherwise be
able to pay, cover quadrivalent HPV vaccine for males.
Adolescents constitute a large part of the age range for which HPV vaccine has been
approved and shown to be efficacious in males [14]. Since parents typically decide whether
their children receive vaccines, acceptability of HPV vaccine to parents is important. Studies
have generally found that parents reported high levels of acceptability of giving HPV
vaccine to their adolescent sons [19,20]. However, all of these studies were conducted prior
to FDA approval of the vaccine for males, and many did not inform parents about the
vaccine’s health benefits for males or the vaccine’s costs [19]. These factors may have
influenced acceptability reported in these earlier studies. In this study, we aimed to
characterize HPV vaccine acceptability following FDA approval of the vaccine for males
among a national sample of mothers with adolescent sons.
2. Materials and Methods
2.1. Participants and Procedures
We used data from a study that recruited a national sample of mothers of adolescent females
aged 11–14 years and examined mother-daughter communication about HPV vaccine. Some
of these mothers also had adolescent sons aged 9–18 years, the focus of this report. All
mothers were members of an existing national panel of U.S. households. The panel was
composed using a dual frame approach combining list-assisted, random-digit dialing and
address-based sample frames, which provided a probability-based sample of US households.
The survey company provides households containing one or more panel members with free
internet access in exchange for panel members completing multiple internet-based surveys
each month. In households with existing computer and internet access, panel members
accumulate points for completing surveys. The points can be redeemed for small cash
payments at regular intervals.
The survey company invited 1,681 mothers to participate in our study, of whom 1,170
responded to the invitation. Among mothers who responded, 1,009 had a daughter aged 11–
14 years and were thus eligible to participate in the study. A total of 951 mothers of
adolescent females (response rate = 66% [21]) provided informed consent and completed
our cross-sectional, online survey in December 2009. Mothers who reported also having a
son aged 9–18 years (n=414) received items about HPV vaccination in males. If a mother
had more than one son aged 9–18 years, she was asked to think about the son who had the
most recent birthday when answering these items. We report data on HPV vaccine
acceptability for 406 mothers, excluding mothers who indicated their sons had already
received HPV vaccine (n=2) and those who did not provide complete HPV vaccine
acceptability data (n=6). The Institutional Review Board at the University of North Carolina
approved the study.
2.2. Measures
We developed survey items based on our previous HPV vaccine research among females,
parents, and healthcare providers [22–24]. We cognitively tested the survey with mothers of
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adolescent children prior to the study to ensure survey instructions and items were clear and
to confirm that participants interpreted survey items as we intended. The survey measured
demographics and constructs we felt may be important to a study occurring only a few
months post-HPV vaccine licensure for males.
Prior to asking mothers about their sons and HPV vaccine, the survey provided an
informative statement about HPV vaccine and males: “An HPV vaccine is now available for
use in boys and young men 9–26 years old. It protects against most genital warts and may
provide some protection against different types of cancer, including oral and anal cancers. It
requires 3 doses (or shots) over 6 months.” The survey then assessed whether mothers had
heard prior to this survey that HPV vaccine can be given to boys and whether their sons had
received any doses of HPV vaccine.
To ensure that mothers were also aware that HPV vaccine may provide health benefits for
their sons’ sexual partners, the survey next provided mothers with a second informative
statement: “Vaccinating boys against HPV may also provide protection against genital warts
and cervical cancer for their future spouses or girlfriends.” The survey measured how
important it was to mothers that HPV vaccine may protect their sons’ future spouses or
girlfriends from HPV-related disease with a 4-point scale ranging from “not important at all”
to “very important” (coded 1–4).
The survey then assessed mothers’ willingness to get their sons HPV vaccine using two
items: “How willing would you be to get the HPV vaccine for your son if it was free?” and
“How willing would you be to get the HPV vaccine for your son if it cost $400 out of
pocket?”. Response options were “definitely not willing,” “probably not willing,” “not
sure,” “probably willing,” and “definitely willing” for both items (coded 1–5).
Mothers indicated if they had talked with their sons about HPV vaccine. The survey
measured mothers’ knowledge about HPV and HPV vaccine using three items about
whether HPV is an STI, HPV vaccine can prevent most genital warts, and HPV vaccine
prevents most cervical cancer. These items were asked prior to mothers receiving the
informative statements about HPV vaccine and males. The survey provided response options
of “yes”, “no”, and “I don’t know” for each knowledge item. We summed the number of
correct responses provided by each mother for the three items, coding responses of “no” and
“I don’t know” as incorrect. The survey also examined whether mothers’ adolescent
daughters (i.e., the adolescent sons’ sisters) had received any doses of HPV vaccine.
In addition to their sons’ ages, mothers provided information on various other demographic
characteristics and health behaviors (Table 1). We defined “urban” as living in a
metropolitan statistical area (MSA) and “rural” as living outside of an MSA [25]. The
survey measured political affiliation with a 5-point scale ranging from “very conservative”
to “very liberal” (coded 1–5), while importance of religion was measured with a 4-point
scale ranging from “not important at all” to “very important” (coded 1–4).
2.3. Data Analysis
We used a paired t-test to compare mothers’ willingness to get their sons HPV vaccine if the
vaccine were free or cost $400 out of pocket. We used linear regression to examine
correlates of mothers’ willingness to get their sons HPV vaccine if: 1) it were free, and 2) it
cost $400 out of pocket. We constructed a separate multivariate model for each outcome,
though both models contained the same independent variables (those associated with either
willingness outcome (p<0.05) in bivariate analyses). We report standardized regression
coefficients from these linear regressions. To determine if coefficients differed between the
two models, we used repeated measures analysis of variance (ANOVA). Analyses used
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SPSS version 17.0 (SPSS Inc., Chicago IL), and statistical tests were two-tailed, using a
critical alpha of 0.05.
3. Results
3.1. Participant Characteristics
Most mothers were age 40 or older (71%), non-Hispanic white (79%), married or living with
a partner (89%), employed (67%), and reported a household income of at least $60,000
(66%) (Table 1). Half of mothers had a college degree. The sample included mothers from
all four geographic regions of the U.S. and primarily from urban areas (86%). The mean age
among sons was 13.2 years (standard deviation [SD]=2.8 years), with 42% aged 9–12 years,
31% aged 13–15 years, and 27% aged 16–18 years.
3.2. HPV and HPV Vaccine
Mothers, on average, had fairly low knowledge about HPV and HPV vaccine, answering
only 43% of the knowledge questions correctly (mean=1.3 of three items correct). Most
knew that HPV is an STI (62%), but fewer knew HPV vaccine can prevent most cervical
cancer (47%) and genital warts (20%). About 30% of mothers’ adolescent daughters aged
11–14 years had received any doses of HPV vaccine. Only 15% of mothers were aware prior
to the survey that HPV vaccine can be given to boys, and fewer (10%) had talked with their
sons about the vaccine. Mothers thought it was important that HPV vaccine may protect
their sons’ future spouses or girlfriends from HPV-related disease (mean=3.0 [possible
range 1–4], SD=1.1).
3.3. Willingness to Get Sons HPV Vaccine
Mothers reported moderate levels of willingness to get their sons HPV vaccine if the vaccine
were free (mean=3.3 [possible range 1–5], SD=1.4), with 47% definitely or probably willing
to vaccinate (Figure 1). Mothers were less willing to get their sons HPV vaccine if the
vaccine cost $400 out of pocket (mean=2.1 [possible range 1–5], SD=1.1) (paired t=19.88,
p<0.001). Only 11% of mothers were definitely or probably willing to vaccinate if the three
dose series cost $400. Many mothers were not sure how willing they would be to vaccinate
if the vaccine were free (25%) or if it cost $400 (26%).
In multivariate analysis, willingness to get their sons free HPV vaccine was higher among
mothers who reported higher levels of importance that HPV vaccine may protect their sons’
future spouses or girlfriends from HPV-related disease (β=0.59) (Table 2). Mothers were
also more willing to get their sons free HPV vaccine if they were aged 40–49 years
(compared to those aged less than 40 years) (β=0.08), not married or living with a partner
(β=0.08), had higher HPV and HPV vaccine knowledge (β=0.08), or if their adolescent
daughters had received any doses of HPV vaccine (β=0.15). Mothers who reported higher
levels of religion importance (β=−0.09) or were aware prior to the survey that HPV vaccine
can be given to boys (β=−0.07) were less willing to get their sons free HPV vaccine.
Willingness to get their sons HPV vaccine if it cost $400 out of pocket was higher among
mothers who reported higher levels of importance that HPV vaccine may protect their sons’
future spouses or girlfriends from HPV-related disease (β=0.49), had higher HPV and HPV
vaccine knowledge (β=0.09), or had adolescent daughters who had received any doses of
HPV vaccine (β=0.11) (Table 2). Mothers were also more willing to pay $400 to get their
sons HPV vaccine if they were non-Hispanic African American (compared to non-Hispanic
white)(β=0.16) or reported a household income of at least $60,000 (β=0.14). Non-Hispanic
mothers of other races (not white or African American) reported lower willingness to pay
for HPV vaccine than non-Hispanic white mothers (β=−0.08).
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Several variables more strongly predicted mothers’ willingness to get free HPV vaccine than
willingness to pay for the vaccine (marital status, awareness that HPV vaccine can be given
to boys, and importance that the vaccine may protect their sons’ future spouses or
girlfriends; all p<0.05) (Table 2). The opposite was true for race and household income,
which were both more strongly associated with willingness to pay for the vaccine (both
p<0.05). While estimates for political affiliation were on opposite sides of zero and differed
in size from one another, political affiliation was not correlated with either willingness
outcome.
4. Discussion
4.1. Main Findings
Soon after the ACIP gave a provisional permissive recommendation for HPV vaccination
for males [17], a national sample of mothers with adolescent sons were moderately willing
to get their sons free HPV vaccine but much less willing to pay $400 out of pocket for the
vaccine. To our knowledge, this is the first estimate of parents’ willingness to get their sons
HPV vaccine following FDA approval and provisional ACIP recommendations.
Acceptability of HPV vaccine for their adolescent son was lower than previous estimates
among parents in the U.S. and elsewhere, which were typically well over 50% [19,20,26–
28]. This was somewhat surprising since many of these previous studies did not inform
parents about the vaccine’s potential health benefits for males and their sexual partners [19].
These studies, however, occurred prior to FDA licensure of HPV vaccine for males in the
U.S., meaning acceptability estimates could have been inflated since vaccination was
hypothetical. Our findings may more accurately represent parents’ actual HPV vaccine
acceptability for adolescent males.
Our results also highlight the importance of health insurance coverage for HPV vaccination
in males, as mothers’ willingness to vaccinate their sons was much lower if the vaccine cost
$400 out of pocket. While many health insurance plans and the VFC program may cover the
vaccine for males, failure to do so could result in extremely low HPV vaccine coverage
among adolescent males. This may be particularly true among families with lower incomes,
as mothers reporting household incomes of less than $60,000 were less willing to pay for
HPV vaccine. Household income was not, however, associated with mothers’ willingness to
get their sons free HPV vaccine. HPV vaccination levels among adolescent females in the
U.S. remain modest (about 37% have received one or more doses [29]), despite most
insurance health insurance plans covering the vaccine and high initial hypothetical
acceptability to parents (55% to 100%) [30]. Future efforts should assess HPV vaccination
levels among males to determine how acceptability of the vaccine to parents translates into
vaccine uptake.
Regardless of whether HPV vaccine was free or cost money out of pocket, the strongest
correlate of mothers’ willingness was importance that the vaccine may protect their sons’
future spouses or girlfriends from HPV-related disease. Currently, quadrivalent HPV
vaccine is licensed for males only to prevent genital warts [14,17,18], and parents have
indicated that the vaccine’s potential health benefits for their sons would be their main
reason to vaccinate [26]. However, if future research supports HPV vaccine reducing
cervical disease in males’ sexual partners, it will be important to include this additional
benefit in framing HPV vaccine to parents. This framing approach, however, may not be as
effective among adult males, as informing them that HPV vaccine may benefit their female
partners has not increased their willingness to get vaccinated in past studies [31,32]. Instead,
informing adult males that HPV vaccine may prevent cancer in males, as opposed to only
genital warts, could be an effective strategy (if future research supports this claim) [33].
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Most mothers were not aware prior to the survey that boys could receive HPV vaccine,
which was likely due to our survey being completed about two months following FDA
approval of the vaccine for use in males. Mothers who were aware of this reported lower
levels of willingness to get their sons free HPV vaccine, perhaps because mothers who were
better informed had spent more time thinking about the potential costs and barriers as well
as the benefits of vaccinating their sons. Interestingly, mothers who were aware did not have
higher levels of knowledge about HPV and HPV vaccine compared to mothers who were
not aware (data not shown). It is therefore possible that aware mothers were also less willing
to vaccinate due to misinformation about HPV and HPV vaccine. Mothers with low
knowledge who were willing to vaccinate may simply have high acceptability of vaccines
for their children in general. Given that knowledge was generally low and greater
knowledge was positively correlated with HPV vaccine acceptability, future educational
efforts about HPV and HPV vaccine are needed for parents with adolescent sons. Such
efforts may be especially beneficial for those mothers who are unsure about whether they
would vaccinate their sons.
Mothers whose adolescent daughters had received HPV vaccine were more willing to get
their sons HPV vaccine, likely due to these mothers having high overall opinions of HPV
vaccine. Mothers who reported higher levels of importance of religion were less willing to
get their sons free HPV vaccine. This finding coincides with HPV vaccine acceptability
research among parents of females, where parents who attended religious services more
frequently reported lower vaccine acceptability [34]. Non-Hispanic African American
mothers were more willing to pay $400 out of pocket for HPV vaccine, which is
encouraging since it is more common for non-Hispanic African American males to have had
an HPV type contained in the quadrivalent vaccine compared to other races [35]. While
parents have generally been more willing to vaccinate older female adolescents against HPV
[30], sons’ age was not correlated with mothers’ willingness.
4.2. Strengths and Limitations
Study strengths include the use of a sample from a national online survey panel, a high
participation rate, that data collection occurred after FDA approval and provisional ACIP
recommendations for males, and that we informed mothers about the vaccine’s potential
health benefits for males and their sexual partners prior to willingness items. Although the
online panel closely resembles the U.S. population on many demographic features [36,37],
most participants were non-Hispanic white and of fairly high socioeconomic status. The
panel also regularly completes surveys, possibly including some health-related surveys,
which might affect their responses. The item examining importance of HPV vaccine
possibly protecting sons’ future female partners from HPV-related disease may in part
represent some aspect of overall HPV vaccine acceptability, though we believe this item
measures an important parental belief. While we did not have information on some variables
that may be related to HPV vaccine acceptability, such as sons’ insurance coverage, the
importance of a doctor’s recommendation to get vaccinated, and beliefs about the vaccine
(e.g., perceived effectiveness), some of these will become important only later as the vaccine
is more widely understood by parents.
4.3. Conclusions
Mothers were moderately willing to get their sons HPV vaccine if it were free and much less
willing if it cost money, suggesting that cost and health insurance coverage will be important
factors in determining whether mothers get their sons vaccinated. Informing mothers that the
vaccine may benefit their sons’ sexual partners and increasing mothers’ HPV and HPV
vaccine knowledge could increase their willingness to get their sons vaccinated. Future
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research is needed to examine changes in acceptability of HPV vaccine for sons and vaccine
uptake among males over time as more data become available on vaccine efficacy in males.
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Figure 1.
Mothers’ willingness to get their adolescent sons human papillomavirus (HPV) vaccine
(n=406).
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Table 1
Characteristics of mothers and their adolescent sons (n=406).
n (%)
Son Characteristics
Age (Years)
  9–12 171 (42)
  13–15 126 (31)
  16–18 109 (27)
Sister Aged 11–14 Years Received Any Doses of HPV
Vaccine
  No/Don't Know (n=8) 284 (70)
  Yes 122 (30)
Mother Characteristics
Age (Years)
  <40 119 (29)
  40–49 238 (59)
  50+ 49 (12)
Race/Ethnicity
  White, Non-Hispanic 321 (79)
  African American, Non-Hispanic 27 (7)  
  Other Race, Non-Hispanic 23 (6)  
  Hispanic 35 (9)  
Marital Status
  Divorced, Widowed, Separated, Never Married 45 (11)
  Married or Living with Partner 361 (89)
Education Level
  No College Degree 202 (50)
  College Degree 204 (50)
Employment Status
  Not Currently Employed 136 (33)
  Currently Employed 270 (67)
Born-again Christian
  No/Don't Know (n=1) 261 (64)
  Yes 145 (36)
Importance of Religiona, mean (SD) 3.3 (1.0)
Political Affiliationb, mean (SD) 2.4 (1.1)
Ever Had an Abnormal Pap Smear
  No/Don't Know (n=3) 264 (65)
  Yes 142 (35)
HPV and HPV Vaccine Knowledgec, mean (SD) 1.3 (0.9)
Aware HPV Vaccine Can Be Given to Boys
  No/Don't Know (n=1) 344 (85)
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n (%)
  Yes 62 (15)
Talked with Son About HPV Vaccine
  No/Don't Know (n=3) 366 (90)
  Yes 40 (10)
Importance that HPV Vaccine Could Protect Son's Future
Spouse or Girlfrienda, mean (SD)
3.0 (1.1)
Household Characteristics
Household Income
  <$60,000 138 (34)
  ≥$60,000 268 (66)
Urbanicity
  Rural 57 (14)
  Urban 349 (86)
Region of Residence
  Northeast 63 (16)
  Midwest 127 (31)
  West 116 (29)
  South 100 (25)
Note. HPV = human papillomavirus, SD = standard deviation.
a
Response scale: not important at all (coded as 1), slightly important (2), fairly important (3), very important (4).
b
Response scale: very conservative (coded as 1), somewhat conservative (2), moderate (3), somewhat liberal (4), very liberal (5).
c
Knowledge score calculated by summing the number of correct responses to three items.
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